Pharma Journalist -

Eli Lilly and Company and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial…
Read More...

Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and…
Read More...

AbbVie announced that it has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI …
Read More...

Icosavax, Inc. announced the close of a $100 million Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global…
Read More...

CytoDyn Inc. a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced it has executed an…
Read More...

SMi Group Reports: Keynote FDA speakers, Qiao Bobo and John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place virtually in just 3 weeks’ time on…
Read More...

AIM ImmunoTech Inc. announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious…
Read More...

AB Science SA together with the University of Chicago, announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans…
Read More...

Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for…
Read More...

Progenity, Inc. a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced an agreement with Ionis…
Read More...